LKT Labs

Biochemicals for Life Science Research

Tozasertib

Tozasertib

Product ID T5996
Cas No. 639089-54-6
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $60.10 In stock
25 mg $105.30 In stock
100 mg $375.60 In stock
250 mg $721.20 In stock
Bulk Quote

Quicklinks

Description

Tozasertib is an anticancer chemotherapeutic pan-aurora kinase (AurK) inhibitor that also inhibits FMS-like tyrosine kinase 3 (FLT3) and Abl. Tozasertib is currently in clinical trials as a potential treatment for acute lymphoblastic leukemia (ALL). In cellular models of cancer, tozasertib activates caspase-3 and PARP and decreases expression of HDAC, increasing apoptosis and inhibiting cell growth. In other cellular models, tozasertib inhibits cell proliferation and metastasis by blocking downstream ERK signaling and downregulating cdc25c and cyclin B. This compound also decreases tumor growth in an in vivo model of prostate cancer.

Product Info

Cas No.

639089-54-6
Purity

≥98%
Formula

C23H28N8OS
Formula Wt.

464.59
Chemical Name

N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino] pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide
IUPAC Name

N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino] pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide
Synonym

VX680, MK0457
Melting Point

245-260°C
Solubility

DMSO at 100 mg/mL
Appearance

White to pale yellow powder

Shipping and Storage

Store Temp

Ambient
Ship Temp

Ambient

Downloads

MSDS

T5996 MSDS PDF
Info Sheet

T5996 Info Sheet PDF

References

Okabe S, Tauchi T, Tanaka Y, et al. Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. Cancer Cell Int. 2013 Apr 4;13(1):32. PMID: 23556431.

Li Y, Zhou W, Wei L, et al. The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma. Int J Oncol. 2012 Dec;41(6):2139-49. PMID: 23007526.

Giles FJ, Swords RT, Nagler A, et al. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia. 2013 Jan;27(1):113-7. PMID: 22772060.

Jeet V, Russell PJ, Verma ND, et al. Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer. Curr Cancer Drug Targets. 2012 Feb;12(2):144-63. PMID: 22229247.

Salah E, Ugochukwu E, Barr AJ, et al. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. J Med Chem. 2011 Apr 14;54(7):2359-67. PMID: 21417343.

Oliveira TM, Ahmad R, Engh RA. VX680 binding in Aurora A: π-π interactions involving the conserved aromatic amino acid of the flexible glycine-rich loop. J Phys Chem A. 2011 Apr 28;115(16):3895-904. PMID: 21306143.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • T0154

    Tanshinone IIA

    Found in Salvia; MAG lipase inhibitor.

    ≥93%
  • K1650

    Kemptide

    PKA substrate.

    ≥95%
  • C4556

    Clofibric Acid

    Metabolite of clofibrate; PPARα agonist.

    ≥98%
  • S0170

    Sarafloxacin Hydrochloride

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥95%
  • C0020

    Cafestol

    Diterpene found in brewed, unfiltered coffee; F...

    ≥98%
  • C0247

    Calcineurin Autoinhibitory Peptide

    Peptide; calcineurin inhibitor.

    ≥95%
  • M5877

    Motesanib Diphosphate

    VEGFR, PDGFR, c-Kit, RET inhibitor.

    ≥98%
  • E6995

    Erythromycin Ethylsuccinate

    Macrolide; protein translation inhibitor, mamma...

    ≥97%
  • K0054

    Kanamycin B

    Aminoglycoside; protein translation inhibitor, ...

    ≥98%
  • D170310

    10,11-Dehydrocurvularin

    Fungal metabolite produced by Penicillium speci...

    ≥98%
  • G6802

    Granisetron Hydrochloride

    5-HT3 antagonist.

    ≥98%
  • C0150

    Camptothecin

    Quinolone alkaloid precursor of irinotecan, ori...

    ≥98%
  • A5285

    [Ile7]-Angiotensin III

    Peptide, derivative of AT III, cleavage product...

    ≥95%
  • P3600

    PJ34 Hydrochloride

    PARP inhibitor; potential Pim1 inhibitor.

    ≥95%
  • M1708

    Mecamylamine Hydrochloride

    Monoterpene; nAChR antagonist.

    ≥98%
  • A5235

    Amitriptyline Hydrochloride

    FIASMA, σ1, RyR2, TrkA/B agonist; SERT, NET in...

    ≥98%
  • P0932

    PCI-32765

    BTK and IL-2-inducible kinase inhibitor.  
    ≥99%
  • D3322

    Diflunisal

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • R5611

    Rocuronium Bromide

    Non-depolarizing NMJ blocker; nAChR and M2/3 mA...

    ≥98%
  • P691320

    PRI-724

    Wnt/beta-catenin/CBP inhibitor

    ≥98%